DNTH
Price
$17.61
Change
+$2.01 (+12.88%)
Updated
Apr 11 closing price
Capitalization
565.74M
PRME
Price
$1.33
Change
+$0.16 (+13.68%)
Updated
Apr 11 closing price
Capitalization
174.44M
27 days until earnings call
Ad is loading...

DNTH vs PRME

Header iconDNTH vs PRME Comparison
Open Charts DNTH vs PRMEBanner chart's image
Dianthus Therapeutics
Price$17.61
Change+$2.01 (+12.88%)
Volume$304.3K
Capitalization565.74M
Prime Medicine
Price$1.33
Change+$0.16 (+13.68%)
Volume$1.76M
Capitalization174.44M
DNTH vs PRME Comparison Chart
Loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. PRME commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Hold and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 12, 2025
Stock price -- (DNTH: $17.61 vs. PRME: $1.33)
Brand notoriety: DNTH and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 83% vs. PRME: 122%
Market capitalization -- DNTH: $565.74M vs. PRME: $174.44M
DNTH [@Biotechnology] is valued at $565.74M. PRME’s [@Biotechnology] market capitalization is $174.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • DNTH’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than DNTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • DNTH’s TA Score: 4 bullish, 6 bearish.
  • PRME’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PRME is a better buy in the short-term than DNTH.

Price Growth

DNTH (@Biotechnology) experienced а +9.24% price change this week, while PRME (@Biotechnology) price change was -5.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Reported Earning Dates

DNTH is expected to report earnings on Nov 09, 2023.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNTH($566M) has a higher market cap than PRME($174M). DNTH YTD gains are higher at: -19.220 vs. PRME (-54.452). DNTH has higher annual earnings (EBITDA): -101.45M vs. PRME (-196.34M). DNTH has more cash in the bank: 275M vs. PRME (190M). DNTH has less debt than PRME: DNTH (1.49M) vs PRME (40.8M). DNTH has higher revenues than PRME: DNTH (6.24M) vs PRME (2.98M).
DNTHPRMEDNTH / PRME
Capitalization566M174M325%
EBITDA-101.45M-196.34M52%
Gain YTD-19.220-54.45235%
P/E Ratio3.24N/A-
Revenue6.24M2.98M209%
Total Cash275M190M145%
Total Debt1.49M40.8M4%
FUNDAMENTALS RATINGS
DNTH vs PRME: Fundamental Ratings
DNTH
PRME
OUTLOOK RATING
1..100
7679
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
39
Fair valued
PROFIT vs RISK RATING
1..100
51100
SMR RATING
1..100
9296
PRICE GROWTH RATING
1..100
9297
P/E GROWTH RATING
1..100
54100
SEASONALITY SCORE
1..100
n/a14

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (39) in the null industry is in the same range as DNTH (55). This means that PRME’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's Profit vs Risk Rating (51) in the null industry is somewhat better than the same rating for PRME (100). This means that DNTH’s stock grew somewhat faster than PRME’s over the last 12 months.

DNTH's SMR Rating (92) in the null industry is in the same range as PRME (96). This means that DNTH’s stock grew similarly to PRME’s over the last 12 months.

DNTH's Price Growth Rating (92) in the null industry is in the same range as PRME (97). This means that DNTH’s stock grew similarly to PRME’s over the last 12 months.

DNTH's P/E Growth Rating (54) in the null industry is somewhat better than the same rating for PRME (100). This means that DNTH’s stock grew somewhat faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNTHPRME
RSI
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 16 days ago
79%
Bullish Trend 24 days ago
78%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 3 days ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCIEX6.85N/A
N/A
Gabelli Equity Income I
FCPVX17.35N/A
N/A
Fidelity Small Cap Value Fund
ABIEX8.11N/A
N/A
AB Emerging Markets Multi-Asset I
BMSBX12.29N/A
N/A
MFS Blended Research Mid Cap Eq B
REPSX34.26N/A
N/A
ProFunds Real Estate UltraSector Svc

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+12.88%
IMNM - DNTH
46%
Loosely correlated
+14.52%
PRME - DNTH
45%
Loosely correlated
+13.68%
COGT - DNTH
44%
Loosely correlated
+5.97%
ERAS - DNTH
43%
Loosely correlated
+16.43%
SYRE - DNTH
43%
Loosely correlated
+2.43%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+13.68%
CRSP - PRME
63%
Loosely correlated
+14.71%
RXRX - PRME
59%
Loosely correlated
+27.72%
BEAM - PRME
57%
Loosely correlated
+5.74%
NTLA - PRME
55%
Loosely correlated
+9.45%
ABCL - PRME
53%
Loosely correlated
+15.94%
More